Cost-effectiveness of screening for hepatitis C in Canada

CMAJ

Volumn 187, Issue 3, 2015, Pages E110-E121

  Wong, William W L ^a   Tu, Hong Anh ^b   Feld, Jordan J ^c   Wong, Tom ^a,d   Krahn, Murray ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PARITAPREVIR; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT;

ADULT; AGED; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; BLOOD EXAMINATION; CANADA; COMBINATION CHEMOTHERAPY; COMPUTER MODEL; COST EFFECTIVENESS ANALYSIS; DECISION SUPPORT SYSTEM; DEPRESSION; DRUG COST; DRUG WITHDRAWAL; FEMALE; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; LIFE EXPECTANCY; LIVER FIBROSIS; MALE; MIDDLE AGED; PREDICTION; PRURITUS; QUALITY ADJUSTED LIFE YEAR; RASH; SCREENING TEST; SEROPREVALENCE; VALIDATION PROCESS; COST BENEFIT ANALYSIS; ECONOMICS; HEPATITIS C, CHRONIC; MASS SCREENING;

ADULT; ANTIVIRAL AGENTS; CANADA; COST-BENEFIT ANALYSIS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MASS SCREENING; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; RIBAVIRIN;

EID: 84923762544     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.140711     Document Type: Article

References (74)

1. Kwong JC, Crowcroft NS, Campitelli MS, et al. Ontario burden of infectious disease study. Toronto: Institute for Clinical Evaluative Sciences; 2010.
2. Shah HA, Heathcote EJ, Feld JJ. A Canadian screening program for hepatitis C: Is now the time? CMAJ 2013;185:1325-8.
3. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012;(RR-4):1-32. Erratum in: MMWR Recomm Rep 2012;61:886.
4. Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int 2012;32 Suppl 1:88-102.
5. Sherman M, Shafran S, Burak K, et al. Management of chronic hepatitis C: consensus guidelines. Can J Gastroenterol 2007;21 Suppl C:25C-34C.
6. Myers RP, Ramji A, Bilodeau M, et al. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol 2012;26:359-75.
7. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014;370:1993-2001.
8. Manns M, Marcellin P, Poordad F, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014;384:414-26.
9. Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014;384:403-13.
10. Poordad F, Hezode C, Trinh R, et al. ABT-450/r-Ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370:1973-82.
11. Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1594-603.
12. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-87.
13. CADTH therapeutic review: direct-acting antiviral agents for chronic hepatitis C genotype 1. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2014.
14. Common drug review drug database. Ottawa: Canadian Agency for Drugs and Technologies in Health. Available: www.cadth.ca/en/products/cdr/search (accessed 2014 Nov. 25).
15. Rotermann M, Langlois K, Andonov A, et al. Seroprevalence of hepatitis B and C virus infections: results from the 2007 to 2009 and 2009 to 2011 Canadian Health Measures Survey. Health Rep 2013;24:3-13.
16. Hepatitis: Ontario's use of funding provided by the federal hepatitis C undertaking agreement. Toronto: Ontario Ministry of Health and Long-Term Care; 2007.
17. TreeAge 2013 professional [software]. Williamstown (MA): TreeAge Software; 2013.
18. Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006;130:1086-97.
19. Berg T, Weich V, Teuber G, et al. Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology 2009;50:369-77.
20. Bronowicki JP, Ouzan D, Asselah T, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006;131:1040-8.
21. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
22. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
23. Hézode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-50.
24. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16.
25. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010;376:705-16. Erratum in: Lancet 2010;376:1224.
26. Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008;47:43-50.
27. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
28. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-38.
29. McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-93.
30. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-206.
31. Roberts SK, Weltman MD, Crawford DH, et al. Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial. Hepatology 2009;50:1045-55.
32. Zeuzem S, Diago M, Gane E, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004;127:1724-32.
33. Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;40:993-9.
34. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-17.
35. Rizzetto M. Treatment of hepatitis C virus genotype 2 and 3 with pegylated interferon plus ribavirin [letter]. J Hepatol 2005;42:275-6, author reply 276-7.
36. von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;129:522-7.
37. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357:124-34.
38. Yu ML, Dai CY, Huang JF, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007;56:553-9.
39. Hasan F, Asker H, Al-Khaldi J, et al. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 2004;99:1733-7.
40. Alfaleh FZ, Hadad Q, Khuroo MS, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Liver Int 2004;24:568-74.
41. Kamal SM, El Tawil AA, Nakano T, et al. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005;54:858-66.
42. Sullivan P. New price tag put on liver transplants. CMAJ 2003;168:206.
43. Gao X, Stephens JM, Carter JA, et al. Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C. Expert Rev Pharmacoecon Outcomes Res 2012;12:335-43.
44. Schedule of laboratory fees. Toronto: Ontario Ministry of Health and Long-Term Care; updated 2012. Available: www.health.gov.on.ca/english/providers/program/ohip/sob/lab/labfimmu.html (accessed 2014 May 1).
45. Chen W. Chronic hepatitis C among immigrants living in Canada: natural history, disease burden, and cost-effectiveness of screening [dissertation]. Toronto: University of Toronto; 2010.
46. Maddigan SL, Feeny DH, Johnson JA. Health-related quality of life deficits associated with diabetes and comorbidities in a Canadian National Population Health Survey. Qual Life Res 2005;14:1311-20.
47. Hsu PC, Federico CA, Krajden M, et al. Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection. J Gastroenterol Hepatol 2012;27:149-57.
48. McLernon DJ, Dillon J, Donnan PT. Health-state utilities in liver disease: a systematic review. Med Decis Making 2008;28:582-92.
49. Yeung LT, To T, King SM, et al. Spontaneous clearance of childhood hepatitis C virus infection. J Viral Hepat 2007;14:797-805.
50. Rein DB, Smith BD, Wittenborn JS, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in US primary care settings. Ann Intern Med 2012;156:263-70.
51. Chaudhary R, Tepper M, Eisaadany S, et al. Distribution of hepatitis C virus genotypes in Canada: results from the LCDC Sentinel Health Unit Surveillance System. Can J Infect Dis 1999;10:53-6.
52. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998;28:823-30.
53. Thein HH, Yi Q, Dore GJ, et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008;48:418-31.
54. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-93.
55. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009;27:1485-91.
56. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44:217-31.
57. Krahn M, Wong JB, Heathcote J, et al. Estimating the prognosis of hepatitis C patients infected by transfusion in Canada between 1986 and 1990. Med Decis Making 2004;24:20-9.
58. rd ed. Toronto: Canadian Agency for Drugs and Technologies in Health; 2006. Available: www.cadth.ca/media/pdf/186-EconomicGuidelines-e.pdf (accessed 2014 Nov. 25).
59. Krajden M, Kuo M, Zagorski B, et al. Health care costs associated with hepatitis C: a longitudinal cohort study. Can J Gastroenterol 2010;24:717-26.
60. Salomon JA, Weinstein MC, Hammitt JK, et al. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003;290:228-37.
61. Wong JB, Bennett WG, Koff RS, et al. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA 1998;280:2088-93.
62. Eckman MH, Talal AH, Gordon SC, et al. Cost-effectiveness of screening for chronic hepatitis C infection in the United States. Clin Infect Dis 2013;56:1382-93.
63. Liu S, Cipriano LE, Holodniy M, et al. Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States. PLoS ONE 2013;8:e58975.
64. Sherman M. Hepatitis C: the juggernaut rolls on unchecked. Can J Gastroenterol 2008;22:355-6.
65. Myers RP, Liu M, Shaheen AA. The burden of hepatitis C virus infection is growing: a Canadian population-based study of hospitalizations from 1994 to 2004. Can J Gastroenterol 2008;22:381-7.
66. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879-88.
67. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-98.
68. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483-93.
69. Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1604-14.
70. Saab S, Brezina M, Gitnick G, et al. Hepatitis C screening strategies in hemodialysis patients. Am J Kidney Dis 2001;38:91-7.
71. Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis 2012;55 Suppl 1:S10-5.
72. Tomkins SE, Elford J, Nichols T, et al. Occupational transmission of hepatitis C in healthcare workers and factors associated with seroconversion: UK surveillance data. J Viral Hepat 2012;19:199-204.
73. Carney K, Dhalla S, Aytaman A, et al. Association of tattooing and hepatitis C virus infection: a multicenter case-control study. Hepatology 2013;57:2117-23.
74. Strehlow AJ, Robertson MJ, Zerger S, et al. Hepatitis C among clients of health care for the homeless primary care clinics. J Health Care Poor Underserved 2012;23:811-33.